Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients - TCTMD
6/29/2022 12:00:00 AM3 years 8 months ago
by L.A. McKeown
by L.A. McKeown
The secondary analysis from VOYAGER PAD adds reassurance on top of similar data from COMPASS, says Geoffrey Barnes.
In patients withPAD undergoing revascularization, low-dose rivaroxaban (Xarelto; Bayer/Janssen) plus aspirin reduces the risk of venous thromboembolism (VTE) compared with aspirin alone, according to… [+5274 chars]
full article...